Company Overview - CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment [5] - The company employs a proprietary approach to T cell engineering that integrates characteristics of both innate and adaptive immunity, aiming to enhance cancer therapy effectiveness [5] Recent Developments - CERo has issued additional shares of its Series D Preferred Stock to institutional investors, with a total purchase price of up to 5 million previously issued [1] - The gross proceeds from the recent closing are expected to be approximately 2.25 million at the investors' discretion [3] - The net proceeds from this offering will be utilized to leverage recent FDA IND allowances in liquid and solid tumors and to expedite site activation at MDACC [3] Clinical Progress - The company has achieved a significant milestone with the completion of first-in-human dosing for its novel autologous CAR-T therapeutic candidate, CER-1236, targeting TIM 4L in acute myeloid leukemia (AML) [2] - CERo initiated clinical trials for CER-1236 in April 2025, marking its lead product candidate for hematological malignancies [5]
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing